Global FcRn Antibodies Market Growth (Status and Outlook) 2026-2032
The global FcRn Antibodies market size is predicted to grow from US$ 389 million in 2025 to US$ 5465 million in 2032; it is expected to grow at a CAGR of 36.2% from 2026 to 2032.
FcRn Antibodies are therapeutic monoclonal antibodies designed to bind the neonatal Fc receptor (FcRn), inhibit FcRn-mediated IgG recycling, and accelerate the degradation of circulating IgG, including pathogenic autoantibodies and alloantibodies. This study focuses on fully human and humanized anti-FcRn monoclonal antibodies, including IgG1- and IgG4-based formats, delivered through subcutaneous or intravenous administration. Their therapeutic value is concentrated in diseases where pathogenic IgG has a material role in disease biology, with generalized myasthenia gravis currently representing the most established commercial application and development extending into neurological, hematological, rheumatological, endocrine and maternal-fetal immune disorders. Within this market, differentiation increasingly depends on antibody engineering, FcRn-binding characteristics, depth and duration of IgG reduction, dosing frequency, route of administration, safety profile and the ability to translate a common FcRn mechanism into clinically meaningful outcomes across different diseases.
Key Findings
The average gross profit margin of this product is 89%
Generalized myasthenia gravis remains the core commercial indication for FcRn Antibodies
Commercialization now spans multiple FcRn antibody products and major regions
Subcutaneous and intravenous administration create differentiated treatment delivery models
China is entering a new commercialization phase for FcRn Antibodies
Clinical development is expanding across multiple IgG-mediated disease categories
Market Trends
The FcRn Antibodies market is evolving from a single-indication therapeutic concept into a broader antibody platform targeting pathogenic IgG across multiple autoimmune and alloimmune diseases. The first phase of commercialization has validated FcRn blockade in generalized myasthenia gravis, while the next phase is increasingly defined by indication expansion and product differentiation. Development programs are extending into CIDP, Sj?gren's disease, Graves' disease, rheumatoid arthritis, systemic lupus-related indications, warm autoimmune hemolytic anemia and maternal-fetal immune disorders. At the product level, administration convenience is becoming a more important competitive variable: subcutaneous antibodies can support decentralized or potentially home-based treatment models, while intravenous products retain advantages in controlled specialist settings. Recent authorization of additional self-administration methods for rozanolixizumab illustrates the broader movement toward reducing treatment burden. Meanwhile, next-generation FcRn Antibodies are being developed around deeper or more durable IgG reduction, convenient dosing and chronic-disease usability rather than mechanism differentiation alone.
Market Dynamics
Drivers
The principal driver for FcRn Antibodies is the large therapeutic space represented by diseases in which pathogenic IgG autoantibodies or alloantibodies contribute directly to disease activity. FcRn blockade provides a targeted mechanism for reducing circulating IgG by interfering with receptor-mediated recycling, creating a therapeutic approach that differs from broad immunosuppression. Commercial approvals in generalized myasthenia gravis have provided clinical and regulatory validation of the mechanism, while active development programs across neurology, hematology, rheumatology, endocrinology and maternal-fetal immunology broaden the addressable disease base. The ability to apply one biological mechanism to multiple diseases also improves the strategic value of successful FcRn antibody platforms because clinical, manufacturing and pharmacological knowledge can potentially be leveraged across additional indications.
Restraints
The market remains constrained by the economics and operational complexity of chronic biologic therapy. FcRn Antibodies require sophisticated antibody manufacturing, stringent quality control and substantial clinical development investment, while dependence on external manufacturing organizations can introduce capacity, quality and supply risks. Treatment delivery can also affect adoption: intravenous administration requires healthcare infrastructure, while subcutaneous products still need appropriate dosing devices, patient training and adherence management. Because the mechanism intentionally reduces circulating IgG, safety management is also important, particularly with respect to infection monitoring and treatment scheduling around active infections and immunization. These factors can increase the total cost of treatment delivery and raise the evidence threshold required for broad reimbursement and long-term use.
Opportunities
The largest strategic opportunity lies in extending FcRn Antibodies beyond the initial neuromuscular market into additional IgG-driven diseases with limited targeted treatment options. Nipocalimab is being developed across rare autoantibody, rheumatic and maternal-fetal disease categories, including Sj?gren's disease, warm autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn and fetal and neonatal alloimmune thrombocytopenia. Imeroprubart development extends the opportunity into Graves' disease, difficult-to-treat rheumatoid arthritis, Sj?gren's disease, myasthenia gravis, CIDP and other autoimmune indications. This creates a potentially important transition from relatively narrow rare-disease franchises toward broader multi-specialty immunology portfolios. Commercial opportunity will be strongest where FcRn Antibodies can demonstrate not only IgG reduction but also durable clinical benefit, manageable chronic dosing and a clear advantage in patient convenience or treatment sequencing.
Challenges
The key long-term challenge is that FcRn biology is broadly applicable, but clinical efficacy remains disease-specific. Reduction of pathogenic IgG is a strong pharmacodynamic rationale, yet it does not guarantee that every autoimmune disease will respond sufficiently to support registration or commercialization. This risk was highlighted in 2026 when two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoints. Future programs therefore require increasingly precise patient selection, biomarker strategies, dose optimization and endpoint design. As more FcRn Antibodies reach late-stage development, companies must also differentiate products on efficacy durability, safety, route of administration, dosing burden and indication breadth rather than relying only on the novelty of the FcRn mechanism.
Industry Chain Analysis
The FcRn Antibodies industry chain begins with antibody discovery, FcRn-binding optimization, molecular engineering, cell-line and process development, followed by biologic drug-substance manufacturing, formulation, fill-finish, analytical testing and quality control. Midstream value creation is highly concentrated in clinical development, regulatory registration, intellectual property and scalable manufacturing because the commercial value of an FcRn antibody depends on demonstrating consistent pharmacodynamic IgG reduction together with disease-specific efficacy and safety. Some developers use specialized third-party manufacturers for both drug substance and finished product, making manufacturing partnerships and capacity planning an important component of supply-chain execution.
Downstream, commercialization is concentrated in specialty treatment pathways involving neurology, immunology, hematology, rheumatology and other relevant disciplines. The value chain is increasingly shaped by licensing and regional partnership structures as companies seek to combine antibody innovation with local clinical development, registration and commercialization capabilities. Batoclimab illustrates this model: its Greater China development and commercialization rights have moved through collaboration among HanAll Biopharma, Harbour BioMed and CSPC Pharmaceutical Group. Such structures can reduce the need for a single developer to establish a complete global commercial infrastructure while allowing regional partners to contribute regulatory, manufacturing and market-access capabilities.
Segment Insights
From the product-type perspective, the market contains both fully human and humanized FcRn Antibodies, while IgG1- and IgG4-based antibody formats constitute another important differentiation dimension. Commercial experience has demonstrated that different molecular formats can successfully achieve FcRn blockade, making future differentiation increasingly dependent on binding properties, pharmacodynamic performance, safety and dosing characteristics rather than humanization status alone. Rozanolixizumab represents a humanized IgG4 FcRn antibody, while nipocalimab is a fully human IgG1 monoclonal antibody; batoclimab and imeroprubart further expand the fully human antibody pipeline.
Administration route is becoming one of the most commercially relevant segmentation dimensions. Subcutaneous FcRn Antibodies offer the possibility of shorter administration, decentralized treatment and greater potential for home use, whereas intravenous products remain integrated with specialist infusion-based care. The market also exhibits a clear split between commercialized and investigational products: approved antibodies establish clinical and regulatory validation of FcRn blockade, while investigational candidates increasingly seek differentiation through broader indication strategies, convenient subcutaneous dosing and next-generation pharmacological profiles.
Downstream Market Opportunities
Generalized myasthenia gravis remains the most mature downstream application for FcRn Antibodies and currently provides the clearest commercial validation of the mechanism. The next stage of market expansion is likely to depend on penetration into additional IgG-mediated diseases rather than growth from gMG alone. Neurological applications such as CIDP, hematological diseases such as immune thrombocytopenia and warm autoimmune hemolytic anemia, rheumatological diseases including Sj?gren's disease and rheumatoid arthritis, endocrine autoimmune disease such as Graves' disease, and maternal-fetal disorders such as HDFN and FNAIT represent distinct development pathways with different patient populations and treatment infrastructures. The broadest opportunity therefore lies in building multi-indication FcRn antibody franchises capable of serving multiple specialty markets from a common mechanistic platform.
Regional Insights
North America, Europe and Japan represent the more established commercialization environments for FcRn Antibodies within the confirmed product scope. Rozanolixizumab has been approved and launched across the United States, Europe and Japan, while nipocalimab has received approvals for generalized myasthenia gravis in the United States and Europe. These markets benefit from established rare-disease treatment networks, specialty biologic infrastructure and relatively mature access pathways for targeted immunological therapies. Future regional development will increasingly depend on additional indication approvals and broader adoption outside neuromuscular disease rather than first-market entry alone.
China is becoming an increasingly important regional market as locally generated clinical evidence and domestic commercialization capabilities progress. Batoclimab completed pivotal clinical development for generalized myasthenia gravis in China and has subsequently reached BLA approval, marking an important transition of the Chinese FcRn Antibodies market toward commercialization. The Harbour BioMed-CSPC structure also highlights the importance of local development, manufacturing and commercialization partnerships in translating globally originated FcRn antibody assets into the Chinese market.
Competitive Landscape Analysis
Competition in FcRn Antibodies is characterized by a relatively small group of originators pursuing different combinations of molecular design, administration route, indication breadth and geographic commercialization strategy. Within the confirmed competitive set, UCB has established a commercial position through the subcutaneous antibody rozanolixizumab, while Johnson & Johnson is developing the intravenous nipocalimab franchise around gMG and a broad portfolio of additional autoantibody and maternal-fetal diseases. Immunovant and HanAll Biopharma are focused on fully human FcRn antibodies including batoclimab and next-generation imeroprubart, with development increasingly emphasizing broad indication coverage and subcutaneous convenience. Harbour BioMed and CSPC Pharmaceutical Group form an important Greater China commercialization pathway for batoclimab. Competitive differentiation is therefore shifting from simple target validation toward clinical depth across indications, dosing convenience, durable IgG control, regulatory execution and the ability to build scalable regional commercialization networks. No single competitive advantage is likely to determine market positioning across all indications because clinical requirements and treatment settings differ materially between neurological, hematological, rheumatological and maternal-fetal diseases.
Report Scope
LPI (LP Information)' newest research report, the “FcRn Antibodies Industry Forecast” looks at past sales and reviews total world FcRn Antibodies sales in 2025, providing a comprehensive analysis by region and market sector of projected FcRn Antibodies sales for 2026 through 2032. With FcRn Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world FcRn Antibodies industry.
This Insight Report provides a comprehensive analysis of the global FcRn Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on FcRn Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global FcRn Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for FcRn Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global FcRn Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of FcRn Antibodies market by product type, application, key players and key regions and countries.
Market Segmentation
FcRn Antibodies are therapeutic monoclonal antibodies designed to bind the neonatal Fc receptor (FcRn), inhibit FcRn-mediated IgG recycling, and accelerate the degradation of circulating IgG, including pathogenic autoantibodies and alloantibodies. This study focuses on fully human and humanized anti-FcRn monoclonal antibodies, including IgG1- and IgG4-based formats, delivered through subcutaneous or intravenous administration. Their therapeutic value is concentrated in diseases where pathogenic IgG has a material role in disease biology, with generalized myasthenia gravis currently representing the most established commercial application and development extending into neurological, hematological, rheumatological, endocrine and maternal-fetal immune disorders. Within this market, differentiation increasingly depends on antibody engineering, FcRn-binding characteristics, depth and duration of IgG reduction, dosing frequency, route of administration, safety profile and the ability to translate a common FcRn mechanism into clinically meaningful outcomes across different diseases.
Key Findings
The average gross profit margin of this product is 89%
Generalized myasthenia gravis remains the core commercial indication for FcRn Antibodies
Commercialization now spans multiple FcRn antibody products and major regions
Subcutaneous and intravenous administration create differentiated treatment delivery models
China is entering a new commercialization phase for FcRn Antibodies
Clinical development is expanding across multiple IgG-mediated disease categories
Market Trends
The FcRn Antibodies market is evolving from a single-indication therapeutic concept into a broader antibody platform targeting pathogenic IgG across multiple autoimmune and alloimmune diseases. The first phase of commercialization has validated FcRn blockade in generalized myasthenia gravis, while the next phase is increasingly defined by indication expansion and product differentiation. Development programs are extending into CIDP, Sj?gren's disease, Graves' disease, rheumatoid arthritis, systemic lupus-related indications, warm autoimmune hemolytic anemia and maternal-fetal immune disorders. At the product level, administration convenience is becoming a more important competitive variable: subcutaneous antibodies can support decentralized or potentially home-based treatment models, while intravenous products retain advantages in controlled specialist settings. Recent authorization of additional self-administration methods for rozanolixizumab illustrates the broader movement toward reducing treatment burden. Meanwhile, next-generation FcRn Antibodies are being developed around deeper or more durable IgG reduction, convenient dosing and chronic-disease usability rather than mechanism differentiation alone.
Market Dynamics
Drivers
The principal driver for FcRn Antibodies is the large therapeutic space represented by diseases in which pathogenic IgG autoantibodies or alloantibodies contribute directly to disease activity. FcRn blockade provides a targeted mechanism for reducing circulating IgG by interfering with receptor-mediated recycling, creating a therapeutic approach that differs from broad immunosuppression. Commercial approvals in generalized myasthenia gravis have provided clinical and regulatory validation of the mechanism, while active development programs across neurology, hematology, rheumatology, endocrinology and maternal-fetal immunology broaden the addressable disease base. The ability to apply one biological mechanism to multiple diseases also improves the strategic value of successful FcRn antibody platforms because clinical, manufacturing and pharmacological knowledge can potentially be leveraged across additional indications.
Restraints
The market remains constrained by the economics and operational complexity of chronic biologic therapy. FcRn Antibodies require sophisticated antibody manufacturing, stringent quality control and substantial clinical development investment, while dependence on external manufacturing organizations can introduce capacity, quality and supply risks. Treatment delivery can also affect adoption: intravenous administration requires healthcare infrastructure, while subcutaneous products still need appropriate dosing devices, patient training and adherence management. Because the mechanism intentionally reduces circulating IgG, safety management is also important, particularly with respect to infection monitoring and treatment scheduling around active infections and immunization. These factors can increase the total cost of treatment delivery and raise the evidence threshold required for broad reimbursement and long-term use.
Opportunities
The largest strategic opportunity lies in extending FcRn Antibodies beyond the initial neuromuscular market into additional IgG-driven diseases with limited targeted treatment options. Nipocalimab is being developed across rare autoantibody, rheumatic and maternal-fetal disease categories, including Sj?gren's disease, warm autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn and fetal and neonatal alloimmune thrombocytopenia. Imeroprubart development extends the opportunity into Graves' disease, difficult-to-treat rheumatoid arthritis, Sj?gren's disease, myasthenia gravis, CIDP and other autoimmune indications. This creates a potentially important transition from relatively narrow rare-disease franchises toward broader multi-specialty immunology portfolios. Commercial opportunity will be strongest where FcRn Antibodies can demonstrate not only IgG reduction but also durable clinical benefit, manageable chronic dosing and a clear advantage in patient convenience or treatment sequencing.
Challenges
The key long-term challenge is that FcRn biology is broadly applicable, but clinical efficacy remains disease-specific. Reduction of pathogenic IgG is a strong pharmacodynamic rationale, yet it does not guarantee that every autoimmune disease will respond sufficiently to support registration or commercialization. This risk was highlighted in 2026 when two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoints. Future programs therefore require increasingly precise patient selection, biomarker strategies, dose optimization and endpoint design. As more FcRn Antibodies reach late-stage development, companies must also differentiate products on efficacy durability, safety, route of administration, dosing burden and indication breadth rather than relying only on the novelty of the FcRn mechanism.
Industry Chain Analysis
The FcRn Antibodies industry chain begins with antibody discovery, FcRn-binding optimization, molecular engineering, cell-line and process development, followed by biologic drug-substance manufacturing, formulation, fill-finish, analytical testing and quality control. Midstream value creation is highly concentrated in clinical development, regulatory registration, intellectual property and scalable manufacturing because the commercial value of an FcRn antibody depends on demonstrating consistent pharmacodynamic IgG reduction together with disease-specific efficacy and safety. Some developers use specialized third-party manufacturers for both drug substance and finished product, making manufacturing partnerships and capacity planning an important component of supply-chain execution.
Downstream, commercialization is concentrated in specialty treatment pathways involving neurology, immunology, hematology, rheumatology and other relevant disciplines. The value chain is increasingly shaped by licensing and regional partnership structures as companies seek to combine antibody innovation with local clinical development, registration and commercialization capabilities. Batoclimab illustrates this model: its Greater China development and commercialization rights have moved through collaboration among HanAll Biopharma, Harbour BioMed and CSPC Pharmaceutical Group. Such structures can reduce the need for a single developer to establish a complete global commercial infrastructure while allowing regional partners to contribute regulatory, manufacturing and market-access capabilities.
Segment Insights
From the product-type perspective, the market contains both fully human and humanized FcRn Antibodies, while IgG1- and IgG4-based antibody formats constitute another important differentiation dimension. Commercial experience has demonstrated that different molecular formats can successfully achieve FcRn blockade, making future differentiation increasingly dependent on binding properties, pharmacodynamic performance, safety and dosing characteristics rather than humanization status alone. Rozanolixizumab represents a humanized IgG4 FcRn antibody, while nipocalimab is a fully human IgG1 monoclonal antibody; batoclimab and imeroprubart further expand the fully human antibody pipeline.
Administration route is becoming one of the most commercially relevant segmentation dimensions. Subcutaneous FcRn Antibodies offer the possibility of shorter administration, decentralized treatment and greater potential for home use, whereas intravenous products remain integrated with specialist infusion-based care. The market also exhibits a clear split between commercialized and investigational products: approved antibodies establish clinical and regulatory validation of FcRn blockade, while investigational candidates increasingly seek differentiation through broader indication strategies, convenient subcutaneous dosing and next-generation pharmacological profiles.
Downstream Market Opportunities
Generalized myasthenia gravis remains the most mature downstream application for FcRn Antibodies and currently provides the clearest commercial validation of the mechanism. The next stage of market expansion is likely to depend on penetration into additional IgG-mediated diseases rather than growth from gMG alone. Neurological applications such as CIDP, hematological diseases such as immune thrombocytopenia and warm autoimmune hemolytic anemia, rheumatological diseases including Sj?gren's disease and rheumatoid arthritis, endocrine autoimmune disease such as Graves' disease, and maternal-fetal disorders such as HDFN and FNAIT represent distinct development pathways with different patient populations and treatment infrastructures. The broadest opportunity therefore lies in building multi-indication FcRn antibody franchises capable of serving multiple specialty markets from a common mechanistic platform.
Regional Insights
North America, Europe and Japan represent the more established commercialization environments for FcRn Antibodies within the confirmed product scope. Rozanolixizumab has been approved and launched across the United States, Europe and Japan, while nipocalimab has received approvals for generalized myasthenia gravis in the United States and Europe. These markets benefit from established rare-disease treatment networks, specialty biologic infrastructure and relatively mature access pathways for targeted immunological therapies. Future regional development will increasingly depend on additional indication approvals and broader adoption outside neuromuscular disease rather than first-market entry alone.
China is becoming an increasingly important regional market as locally generated clinical evidence and domestic commercialization capabilities progress. Batoclimab completed pivotal clinical development for generalized myasthenia gravis in China and has subsequently reached BLA approval, marking an important transition of the Chinese FcRn Antibodies market toward commercialization. The Harbour BioMed-CSPC structure also highlights the importance of local development, manufacturing and commercialization partnerships in translating globally originated FcRn antibody assets into the Chinese market.
Competitive Landscape Analysis
Competition in FcRn Antibodies is characterized by a relatively small group of originators pursuing different combinations of molecular design, administration route, indication breadth and geographic commercialization strategy. Within the confirmed competitive set, UCB has established a commercial position through the subcutaneous antibody rozanolixizumab, while Johnson & Johnson is developing the intravenous nipocalimab franchise around gMG and a broad portfolio of additional autoantibody and maternal-fetal diseases. Immunovant and HanAll Biopharma are focused on fully human FcRn antibodies including batoclimab and next-generation imeroprubart, with development increasingly emphasizing broad indication coverage and subcutaneous convenience. Harbour BioMed and CSPC Pharmaceutical Group form an important Greater China commercialization pathway for batoclimab. Competitive differentiation is therefore shifting from simple target validation toward clinical depth across indications, dosing convenience, durable IgG control, regulatory execution and the ability to build scalable regional commercialization networks. No single competitive advantage is likely to determine market positioning across all indications because clinical requirements and treatment settings differ materially between neurological, hematological, rheumatological and maternal-fetal diseases.
Report Scope
LPI (LP Information)' newest research report, the “FcRn Antibodies Industry Forecast” looks at past sales and reviews total world FcRn Antibodies sales in 2025, providing a comprehensive analysis by region and market sector of projected FcRn Antibodies sales for 2026 through 2032. With FcRn Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world FcRn Antibodies industry.
This Insight Report provides a comprehensive analysis of the global FcRn Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on FcRn Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global FcRn Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for FcRn Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global FcRn Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of FcRn Antibodies market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Fully Human Anti-FcRn Monoclonal Antibodies
- Humanized Anti-FcRn Monoclonal Antibodies
Segmentation by Drugs Type:
- Rozanolixizumab
- Nipocalimab
- Batoclimab
Segmentation by Route of Administration:
- Subcutaneous Anti-FcRn Antibodies
- Intravenous Anti-FcRn Antibodies
Segmentation by Application:
- Generalized Myasthenia Gravis
- Chronic Inflammatory Demyelinating Polyneuropathy
- Thyroid Eye Disease
- Graves' Disease
- Sj?gren's Disease
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- UCB
- Johnson & Johnson
- Immunovant
- HanAll Biopharma
- Harbour BioMed
- CSPC Pharmaceutical Group
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global FcRn Antibodies Market Size (2021-2032)
2.1.2 FcRn Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for FcRn Antibodies by Country/Region (2021, 2025 & 2032)
2.2 FcRn Antibodies Segment by Type
2.2.1 Fully Human Anti-FcRn Monoclonal Antibodies
2.2.2 Humanized Anti-FcRn Monoclonal Antibodies
2.2.3 FcRn Antibodies Market Size by Type
2.2.3.1 FcRn Antibodies Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global FcRn Antibodies Market Size Market Share by Type (2021-2026)
2.3 FcRn Antibodies Segment by Drugs Type
2.3.1 Rozanolixizumab
2.3.2 Nipocalimab
2.3.3 Batoclimab
2.3.4 FcRn Antibodies Market Size by Drugs Type
2.3.4.1 FcRn Antibodies Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032)
2.3.4.2 Global FcRn Antibodies Market Size Market Share by Drugs Type (2021-2026)
2.4 FcRn Antibodies Segment by Route of Administration
2.4.1 Subcutaneous Anti-FcRn Antibodies
2.4.2 Intravenous Anti-FcRn Antibodies
2.4.3 FcRn Antibodies Market Size by Route of Administration
2.4.3.1 FcRn Antibodies Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.3.2 Global FcRn Antibodies Market Size Market Share by Route of Administration (2021-2026)
2.5 FcRn Antibodies Segment by Application
2.5.1 Generalized Myasthenia Gravis
2.5.2 Chronic Inflammatory Demyelinating Polyneuropathy
2.5.3 Thyroid Eye Disease
2.5.4 Graves' Disease
2.5.5 Sj?gren's Disease
2.5.6 Systemic Lupus Erythematosus
2.5.7 Rheumatoid Arthritis
2.5.8 Other
2.5.9 FcRn Antibodies Market Size by Application
2.5.9.1 FcRn Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.9.2 Global FcRn Antibodies Market Size Market Share by Application (2021-2026)
3 FCRN ANTIBODIES MARKET SIZE BY PLAYER
3.1 FcRn Antibodies Market Size Market Share by Player
3.1.1 Global FcRn Antibodies Revenue by Player (2021-2026)
3.1.2 Global FcRn Antibodies Revenue Market Share by Player (2021-2026)
3.2 Global FcRn Antibodies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 FCRN ANTIBODIES BY REGION
4.1 FcRn Antibodies Market Size by Region (2021-2026)
4.2 Global FcRn Antibodies Annual Revenue by Country/Region (2021-2026)
4.3 Americas FcRn Antibodies Market Size Growth (2021-2026)
4.4 APAC FcRn Antibodies Market Size Growth (2021-2026)
4.5 Europe FcRn Antibodies Market Size Growth (2021-2026)
4.6 Middle East & Africa FcRn Antibodies Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas FcRn Antibodies Market Size by Country (2021-2026)
5.2 Americas FcRn Antibodies Market Size by Type (2021-2026)
5.3 Americas FcRn Antibodies Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC FcRn Antibodies Market Size by Region (2021-2026)
6.2 APAC FcRn Antibodies Market Size by Type (2021-2026)
6.3 APAC FcRn Antibodies Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe FcRn Antibodies Market Size by Country (2021-2026)
7.2 Europe FcRn Antibodies Market Size by Type (2021-2026)
7.3 Europe FcRn Antibodies Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa FcRn Antibodies by Region (2021-2026)
8.2 Middle East & Africa FcRn Antibodies Market Size by Type (2021-2026)
8.3 Middle East & Africa FcRn Antibodies Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL FCRN ANTIBODIES MARKET FORECAST
10.1 Global FcRn Antibodies Forecast by Region (2027-2032)
10.1.1 Global FcRn Antibodies Forecast by Region (2027-2032)
10.1.2 Americas FcRn Antibodies Forecast
10.1.3 APAC FcRn Antibodies Forecast
10.1.4 Europe FcRn Antibodies Forecast
10.1.5 Middle East & Africa FcRn Antibodies Forecast
10.2 Americas FcRn Antibodies Forecast by Country (2027-2032)
10.2.1 United States Market FcRn Antibodies Forecast
10.2.2 Canada Market FcRn Antibodies Forecast
10.2.3 Mexico Market FcRn Antibodies Forecast
10.2.4 Brazil Market FcRn Antibodies Forecast
10.3 APAC FcRn Antibodies Forecast by Region (2027-2032)
10.3.1 China FcRn Antibodies Market Forecast
10.3.2 Japan Market FcRn Antibodies Forecast
10.3.3 Korea Market FcRn Antibodies Forecast
10.3.4 Southeast Asia Market FcRn Antibodies Forecast
10.3.5 India Market FcRn Antibodies Forecast
10.3.6 Australia Market FcRn Antibodies Forecast
10.4 Europe FcRn Antibodies Forecast by Country (2027-2032)
10.4.1 Germany Market FcRn Antibodies Forecast
10.4.2 France Market FcRn Antibodies Forecast
10.4.3 UK Market FcRn Antibodies Forecast
10.4.4 Italy Market FcRn Antibodies Forecast
10.4.5 Russia Market FcRn Antibodies Forecast
10.5 Middle East & Africa FcRn Antibodies Forecast by Region (2027-2032)
10.5.1 Egypt Market FcRn Antibodies Forecast
10.5.2 South Africa Market FcRn Antibodies Forecast
10.5.3 Israel Market FcRn Antibodies Forecast
10.5.4 Turkey Market FcRn Antibodies Forecast
10.6 Global FcRn Antibodies Forecast by Type (2027-2032)
10.7 Global FcRn Antibodies Forecast by Application (2027-2032)
10.7.1 GCC Countries Market FcRn Antibodies Forecast
11 KEY PLAYERS ANALYSIS
11.1 UCB
11.1.1 UCB Company Information
11.1.2 UCB FcRn Antibodies Product Offered
11.1.3 UCB FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 UCB Main Business Overview
11.1.5 UCB Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson FcRn Antibodies Product Offered
11.2.3 Johnson & Johnson FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Immunovant
11.3.1 Immunovant Company Information
11.3.2 Immunovant FcRn Antibodies Product Offered
11.3.3 Immunovant FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Immunovant Main Business Overview
11.3.5 Immunovant Latest Developments
11.4 HanAll Biopharma
11.4.1 HanAll Biopharma Company Information
11.4.2 HanAll Biopharma FcRn Antibodies Product Offered
11.4.3 HanAll Biopharma FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 HanAll Biopharma Main Business Overview
11.4.5 HanAll Biopharma Latest Developments
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Information
11.5.2 Harbour BioMed FcRn Antibodies Product Offered
11.5.3 Harbour BioMed FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Harbour BioMed Main Business Overview
11.5.5 Harbour BioMed Latest Developments
11.6 CSPC Pharmaceutical Group
11.6.1 CSPC Pharmaceutical Group Company Information
11.6.2 CSPC Pharmaceutical Group FcRn Antibodies Product Offered
11.6.3 CSPC Pharmaceutical Group FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 CSPC Pharmaceutical Group Main Business Overview
11.6.5 CSPC Pharmaceutical Group Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global FcRn Antibodies Market Size (2021-2032)
2.1.2 FcRn Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for FcRn Antibodies by Country/Region (2021, 2025 & 2032)
2.2 FcRn Antibodies Segment by Type
2.2.1 Fully Human Anti-FcRn Monoclonal Antibodies
2.2.2 Humanized Anti-FcRn Monoclonal Antibodies
2.2.3 FcRn Antibodies Market Size by Type
2.2.3.1 FcRn Antibodies Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global FcRn Antibodies Market Size Market Share by Type (2021-2026)
2.3 FcRn Antibodies Segment by Drugs Type
2.3.1 Rozanolixizumab
2.3.2 Nipocalimab
2.3.3 Batoclimab
2.3.4 FcRn Antibodies Market Size by Drugs Type
2.3.4.1 FcRn Antibodies Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032)
2.3.4.2 Global FcRn Antibodies Market Size Market Share by Drugs Type (2021-2026)
2.4 FcRn Antibodies Segment by Route of Administration
2.4.1 Subcutaneous Anti-FcRn Antibodies
2.4.2 Intravenous Anti-FcRn Antibodies
2.4.3 FcRn Antibodies Market Size by Route of Administration
2.4.3.1 FcRn Antibodies Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.3.2 Global FcRn Antibodies Market Size Market Share by Route of Administration (2021-2026)
2.5 FcRn Antibodies Segment by Application
2.5.1 Generalized Myasthenia Gravis
2.5.2 Chronic Inflammatory Demyelinating Polyneuropathy
2.5.3 Thyroid Eye Disease
2.5.4 Graves' Disease
2.5.5 Sj?gren's Disease
2.5.6 Systemic Lupus Erythematosus
2.5.7 Rheumatoid Arthritis
2.5.8 Other
2.5.9 FcRn Antibodies Market Size by Application
2.5.9.1 FcRn Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.9.2 Global FcRn Antibodies Market Size Market Share by Application (2021-2026)
3 FCRN ANTIBODIES MARKET SIZE BY PLAYER
3.1 FcRn Antibodies Market Size Market Share by Player
3.1.1 Global FcRn Antibodies Revenue by Player (2021-2026)
3.1.2 Global FcRn Antibodies Revenue Market Share by Player (2021-2026)
3.2 Global FcRn Antibodies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 FCRN ANTIBODIES BY REGION
4.1 FcRn Antibodies Market Size by Region (2021-2026)
4.2 Global FcRn Antibodies Annual Revenue by Country/Region (2021-2026)
4.3 Americas FcRn Antibodies Market Size Growth (2021-2026)
4.4 APAC FcRn Antibodies Market Size Growth (2021-2026)
4.5 Europe FcRn Antibodies Market Size Growth (2021-2026)
4.6 Middle East & Africa FcRn Antibodies Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas FcRn Antibodies Market Size by Country (2021-2026)
5.2 Americas FcRn Antibodies Market Size by Type (2021-2026)
5.3 Americas FcRn Antibodies Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC FcRn Antibodies Market Size by Region (2021-2026)
6.2 APAC FcRn Antibodies Market Size by Type (2021-2026)
6.3 APAC FcRn Antibodies Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe FcRn Antibodies Market Size by Country (2021-2026)
7.2 Europe FcRn Antibodies Market Size by Type (2021-2026)
7.3 Europe FcRn Antibodies Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa FcRn Antibodies by Region (2021-2026)
8.2 Middle East & Africa FcRn Antibodies Market Size by Type (2021-2026)
8.3 Middle East & Africa FcRn Antibodies Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL FCRN ANTIBODIES MARKET FORECAST
10.1 Global FcRn Antibodies Forecast by Region (2027-2032)
10.1.1 Global FcRn Antibodies Forecast by Region (2027-2032)
10.1.2 Americas FcRn Antibodies Forecast
10.1.3 APAC FcRn Antibodies Forecast
10.1.4 Europe FcRn Antibodies Forecast
10.1.5 Middle East & Africa FcRn Antibodies Forecast
10.2 Americas FcRn Antibodies Forecast by Country (2027-2032)
10.2.1 United States Market FcRn Antibodies Forecast
10.2.2 Canada Market FcRn Antibodies Forecast
10.2.3 Mexico Market FcRn Antibodies Forecast
10.2.4 Brazil Market FcRn Antibodies Forecast
10.3 APAC FcRn Antibodies Forecast by Region (2027-2032)
10.3.1 China FcRn Antibodies Market Forecast
10.3.2 Japan Market FcRn Antibodies Forecast
10.3.3 Korea Market FcRn Antibodies Forecast
10.3.4 Southeast Asia Market FcRn Antibodies Forecast
10.3.5 India Market FcRn Antibodies Forecast
10.3.6 Australia Market FcRn Antibodies Forecast
10.4 Europe FcRn Antibodies Forecast by Country (2027-2032)
10.4.1 Germany Market FcRn Antibodies Forecast
10.4.2 France Market FcRn Antibodies Forecast
10.4.3 UK Market FcRn Antibodies Forecast
10.4.4 Italy Market FcRn Antibodies Forecast
10.4.5 Russia Market FcRn Antibodies Forecast
10.5 Middle East & Africa FcRn Antibodies Forecast by Region (2027-2032)
10.5.1 Egypt Market FcRn Antibodies Forecast
10.5.2 South Africa Market FcRn Antibodies Forecast
10.5.3 Israel Market FcRn Antibodies Forecast
10.5.4 Turkey Market FcRn Antibodies Forecast
10.6 Global FcRn Antibodies Forecast by Type (2027-2032)
10.7 Global FcRn Antibodies Forecast by Application (2027-2032)
10.7.1 GCC Countries Market FcRn Antibodies Forecast
11 KEY PLAYERS ANALYSIS
11.1 UCB
11.1.1 UCB Company Information
11.1.2 UCB FcRn Antibodies Product Offered
11.1.3 UCB FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 UCB Main Business Overview
11.1.5 UCB Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson FcRn Antibodies Product Offered
11.2.3 Johnson & Johnson FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Immunovant
11.3.1 Immunovant Company Information
11.3.2 Immunovant FcRn Antibodies Product Offered
11.3.3 Immunovant FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Immunovant Main Business Overview
11.3.5 Immunovant Latest Developments
11.4 HanAll Biopharma
11.4.1 HanAll Biopharma Company Information
11.4.2 HanAll Biopharma FcRn Antibodies Product Offered
11.4.3 HanAll Biopharma FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 HanAll Biopharma Main Business Overview
11.4.5 HanAll Biopharma Latest Developments
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Information
11.5.2 Harbour BioMed FcRn Antibodies Product Offered
11.5.3 Harbour BioMed FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Harbour BioMed Main Business Overview
11.5.5 Harbour BioMed Latest Developments
11.6 CSPC Pharmaceutical Group
11.6.1 CSPC Pharmaceutical Group Company Information
11.6.2 CSPC Pharmaceutical Group FcRn Antibodies Product Offered
11.6.3 CSPC Pharmaceutical Group FcRn Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 CSPC Pharmaceutical Group Main Business Overview
11.6.5 CSPC Pharmaceutical Group Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. FcRn Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. FcRn Antibodies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Fully Human Anti-FcRn Monoclonal Antibodies
Table 4. Major Players of Humanized Anti-FcRn Monoclonal Antibodies
Table 5. FcRn Antibodies Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 7. Global FcRn Antibodies Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Rozanolixizumab
Table 9. Major Players of Nipocalimab
Table 10. Major Players of Batoclimab
Table 11. FcRn Antibodies Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global FcRn Antibodies Market Size by Drugs Type (2021-2026) & ($ millions)
Table 13. Global FcRn Antibodies Market Size Market Share by Drugs Type (2021-2026)
Table 14. Major Players of Subcutaneous Anti-FcRn Antibodies
Table 15. Major Players of Intravenous Anti-FcRn Antibodies
Table 16. FcRn Antibodies Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global FcRn Antibodies Market Size by Route of Administration (2021-2026) & ($ millions)
Table 18. Global FcRn Antibodies Market Size Market Share by Route of Administration (2021-2026)
Table 19. FcRn Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 21. Global FcRn Antibodies Market Size Market Share by Application (2021-2026)
Table 22. Global FcRn Antibodies Revenue by Player (2021-2026) & ($ millions)
Table 23. Global FcRn Antibodies Revenue Market Share by Player (2021-2026)
Table 24. FcRn Antibodies Key Players Head office and Products Offered
Table 25. FcRn Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global FcRn Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 29. Global FcRn Antibodies Market Size Market Share by Region (2021-2026)
Table 30. Global FcRn Antibodies Revenue by Country/Region (2021-2026) & ($ millions)
Table 31. Global FcRn Antibodies Revenue Market Share by Country/Region (2021-2026)
Table 32. Americas FcRn Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 33. Americas FcRn Antibodies Market Size Market Share by Country (2021-2026)
Table 34. Americas FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 35. Americas FcRn Antibodies Market Size Market Share by Type (2021-2026)
Table 36. Americas FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 37. Americas FcRn Antibodies Market Size Market Share by Application (2021-2026)
Table 38. APAC FcRn Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 39. APAC FcRn Antibodies Market Size Market Share by Region (2021-2026)
Table 40. APAC FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 41. APAC FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 42. Europe FcRn Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 43. Europe FcRn Antibodies Market Size Market Share by Country (2021-2026)
Table 44. Europe FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 45. Europe FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 46. Middle East & Africa FcRn Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 47. Middle East & Africa FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 48. Middle East & Africa FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 49. Key Market Drivers & Growth Opportunities of FcRn Antibodies
Table 50. Key Market Challenges & Risks of FcRn Antibodies
Table 51. Key Industry Trends of FcRn Antibodies
Table 52. Global FcRn Antibodies Market Size Forecast by Region (2027-2032) & ($ millions)
Table 53. Global FcRn Antibodies Market Size Market Share Forecast by Region (2027-2032)
Table 54. Global FcRn Antibodies Market Size Forecast by Type (2027-2032) & ($ millions)
Table 55. Global FcRn Antibodies Market Size Forecast by Application (2027-2032) & ($ millions)
Table 56. UCB Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 57. UCB FcRn Antibodies Product Offered
Table 58. UCB FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. UCB Main Business
Table 60. UCB Latest Developments
Table 61. Johnson & Johnson Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 62. Johnson & Johnson FcRn Antibodies Product Offered
Table 63. Johnson & Johnson FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Johnson & Johnson Main Business
Table 65. Johnson & Johnson Latest Developments
Table 66. Immunovant Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 67. Immunovant FcRn Antibodies Product Offered
Table 68. Immunovant FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Immunovant Main Business
Table 70. Immunovant Latest Developments
Table 71. HanAll Biopharma Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 72. HanAll Biopharma FcRn Antibodies Product Offered
Table 73. HanAll Biopharma FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. HanAll Biopharma Main Business
Table 75. HanAll Biopharma Latest Developments
Table 76. Harbour BioMed Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 77. Harbour BioMed FcRn Antibodies Product Offered
Table 78. Harbour BioMed FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Harbour BioMed Main Business
Table 80. Harbour BioMed Latest Developments
Table 81. CSPC Pharmaceutical Group Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 82. CSPC Pharmaceutical Group FcRn Antibodies Product Offered
Table 83. CSPC Pharmaceutical Group FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. CSPC Pharmaceutical Group Main Business
Table 85. CSPC Pharmaceutical Group Latest Developments
Table 1. FcRn Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. FcRn Antibodies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Fully Human Anti-FcRn Monoclonal Antibodies
Table 4. Major Players of Humanized Anti-FcRn Monoclonal Antibodies
Table 5. FcRn Antibodies Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 7. Global FcRn Antibodies Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Rozanolixizumab
Table 9. Major Players of Nipocalimab
Table 10. Major Players of Batoclimab
Table 11. FcRn Antibodies Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global FcRn Antibodies Market Size by Drugs Type (2021-2026) & ($ millions)
Table 13. Global FcRn Antibodies Market Size Market Share by Drugs Type (2021-2026)
Table 14. Major Players of Subcutaneous Anti-FcRn Antibodies
Table 15. Major Players of Intravenous Anti-FcRn Antibodies
Table 16. FcRn Antibodies Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global FcRn Antibodies Market Size by Route of Administration (2021-2026) & ($ millions)
Table 18. Global FcRn Antibodies Market Size Market Share by Route of Administration (2021-2026)
Table 19. FcRn Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 21. Global FcRn Antibodies Market Size Market Share by Application (2021-2026)
Table 22. Global FcRn Antibodies Revenue by Player (2021-2026) & ($ millions)
Table 23. Global FcRn Antibodies Revenue Market Share by Player (2021-2026)
Table 24. FcRn Antibodies Key Players Head office and Products Offered
Table 25. FcRn Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global FcRn Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 29. Global FcRn Antibodies Market Size Market Share by Region (2021-2026)
Table 30. Global FcRn Antibodies Revenue by Country/Region (2021-2026) & ($ millions)
Table 31. Global FcRn Antibodies Revenue Market Share by Country/Region (2021-2026)
Table 32. Americas FcRn Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 33. Americas FcRn Antibodies Market Size Market Share by Country (2021-2026)
Table 34. Americas FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 35. Americas FcRn Antibodies Market Size Market Share by Type (2021-2026)
Table 36. Americas FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 37. Americas FcRn Antibodies Market Size Market Share by Application (2021-2026)
Table 38. APAC FcRn Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 39. APAC FcRn Antibodies Market Size Market Share by Region (2021-2026)
Table 40. APAC FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 41. APAC FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 42. Europe FcRn Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 43. Europe FcRn Antibodies Market Size Market Share by Country (2021-2026)
Table 44. Europe FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 45. Europe FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 46. Middle East & Africa FcRn Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 47. Middle East & Africa FcRn Antibodies Market Size by Type (2021-2026) & ($ millions)
Table 48. Middle East & Africa FcRn Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 49. Key Market Drivers & Growth Opportunities of FcRn Antibodies
Table 50. Key Market Challenges & Risks of FcRn Antibodies
Table 51. Key Industry Trends of FcRn Antibodies
Table 52. Global FcRn Antibodies Market Size Forecast by Region (2027-2032) & ($ millions)
Table 53. Global FcRn Antibodies Market Size Market Share Forecast by Region (2027-2032)
Table 54. Global FcRn Antibodies Market Size Forecast by Type (2027-2032) & ($ millions)
Table 55. Global FcRn Antibodies Market Size Forecast by Application (2027-2032) & ($ millions)
Table 56. UCB Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 57. UCB FcRn Antibodies Product Offered
Table 58. UCB FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. UCB Main Business
Table 60. UCB Latest Developments
Table 61. Johnson & Johnson Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 62. Johnson & Johnson FcRn Antibodies Product Offered
Table 63. Johnson & Johnson FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Johnson & Johnson Main Business
Table 65. Johnson & Johnson Latest Developments
Table 66. Immunovant Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 67. Immunovant FcRn Antibodies Product Offered
Table 68. Immunovant FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Immunovant Main Business
Table 70. Immunovant Latest Developments
Table 71. HanAll Biopharma Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 72. HanAll Biopharma FcRn Antibodies Product Offered
Table 73. HanAll Biopharma FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. HanAll Biopharma Main Business
Table 75. HanAll Biopharma Latest Developments
Table 76. Harbour BioMed Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 77. Harbour BioMed FcRn Antibodies Product Offered
Table 78. Harbour BioMed FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Harbour BioMed Main Business
Table 80. Harbour BioMed Latest Developments
Table 81. CSPC Pharmaceutical Group Details, Company Type, FcRn Antibodies Area Served and Its Competitors
Table 82. CSPC Pharmaceutical Group FcRn Antibodies Product Offered
Table 83. CSPC Pharmaceutical Group FcRn Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. CSPC Pharmaceutical Group Main Business
Table 85. CSPC Pharmaceutical Group Latest Developments
LIST OF FIGURES
Figure 1. FcRn Antibodies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global FcRn Antibodies Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. FcRn Antibodies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. FcRn Antibodies Sales Market Share by Country/Region (2025)
Figure 8. FcRn Antibodies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global FcRn Antibodies Market Size Market Share by Type in 2025
Figure 10. Global FcRn Antibodies Market Size Market Share by Drugs Type in 2025
Figure 11. Global FcRn Antibodies Market Size Market Share by Route of Administration in 2025
Figure 12. FcRn Antibodies in Generalized Myasthenia Gravis
Figure 13. Global FcRn Antibodies Market: Generalized Myasthenia Gravis (2021-2026) & ($ millions)
Figure 14. FcRn Antibodies in Chronic Inflammatory Demyelinating Polyneuropathy
Figure 15. Global FcRn Antibodies Market: Chronic Inflammatory Demyelinating Polyneuropathy (2021-2026) & ($ millions)
Figure 16. FcRn Antibodies in Thyroid Eye Disease
Figure 17. Global FcRn Antibodies Market: Thyroid Eye Disease (2021-2026) & ($ millions)
Figure 18. FcRn Antibodies in Graves' Disease
Figure 19. Global FcRn Antibodies Market: Graves' Disease (2021-2026) & ($ millions)
Figure 20. FcRn Antibodies in Sj?gren's Disease
Figure 21. Global FcRn Antibodies Market: Sj?gren's Disease (2021-2026) & ($ millions)
Figure 22. FcRn Antibodies in Systemic Lupus Erythematosus
Figure 23. Global FcRn Antibodies Market: Systemic Lupus Erythematosus (2021-2026) & ($ millions)
Figure 24. FcRn Antibodies in Rheumatoid Arthritis
Figure 25. Global FcRn Antibodies Market: Rheumatoid Arthritis (2021-2026) & ($ millions)
Figure 26. FcRn Antibodies in Other
Figure 27. Global FcRn Antibodies Market: Other (2021-2026) & ($ millions)
Figure 28. Global FcRn Antibodies Market Size Market Share by Application in 2025
Figure 29. Global FcRn Antibodies Revenue Market Share by Player in 2025
Figure 30. Global FcRn Antibodies Market Size Market Share by Region (2021-2026)
Figure 31. Americas FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 32. APAC FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 33. Europe FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 34. Middle East & Africa FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 35. Americas FcRn Antibodies Value Market Share by Country in 2025
Figure 36. United States FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 37. Canada FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 38. Mexico FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 39. Brazil FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 40. APAC FcRn Antibodies Market Size Market Share by Region in 2025
Figure 41. APAC FcRn Antibodies Market Size Market Share by Type (2021-2026)
Figure 42. APAC FcRn Antibodies Market Size Market Share by Application (2021-2026)
Figure 43. China FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 44. Japan FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 45. South Korea FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 46. Southeast Asia FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 47. India FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 48. Australia FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 49. Europe FcRn Antibodies Market Size Market Share by Country in 2025
Figure 50. Europe FcRn Antibodies Market Size Market Share by Type (2021-2026)
Figure 51. Europe FcRn Antibodies Market Size Market Share by Application (2021-2026)
Figure 52. Germany FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 53. France FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 54. UK FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 55. Italy FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 56. Russia FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 57. Middle East & Africa FcRn Antibodies Market Size Market Share by Region (2021-2026)
Figure 58. Middle East & Africa FcRn Antibodies Market Size Market Share by Type (2021-2026)
Figure 59. Middle East & Africa FcRn Antibodies Market Size Market Share by Application (2021-2026)
Figure 60. Egypt FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 61. South Africa FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 62. Israel FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 63. Turkey FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 64. GCC Countries FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 65. Americas FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 66. APAC FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 67. Europe FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 68. Middle East & Africa FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 69. United States FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 70. Canada FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 71. Mexico FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 72. Brazil FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 73. China FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 74. Japan FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 75. Korea FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 76. Southeast Asia FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 77. India FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 78. Australia FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 79. Germany FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 80. France FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 81. UK FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 82. Italy FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 83. Russia FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 84. Egypt FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 85. South Africa FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 86. Israel FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 87. Turkey FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 88. Global FcRn Antibodies Market Size Market Share Forecast by Type (2027-2032)
Figure 89. Global FcRn Antibodies Market Size Market Share Forecast by Application (2027-2032)
Figure 90. GCC Countries FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 1. FcRn Antibodies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global FcRn Antibodies Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. FcRn Antibodies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. FcRn Antibodies Sales Market Share by Country/Region (2025)
Figure 8. FcRn Antibodies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global FcRn Antibodies Market Size Market Share by Type in 2025
Figure 10. Global FcRn Antibodies Market Size Market Share by Drugs Type in 2025
Figure 11. Global FcRn Antibodies Market Size Market Share by Route of Administration in 2025
Figure 12. FcRn Antibodies in Generalized Myasthenia Gravis
Figure 13. Global FcRn Antibodies Market: Generalized Myasthenia Gravis (2021-2026) & ($ millions)
Figure 14. FcRn Antibodies in Chronic Inflammatory Demyelinating Polyneuropathy
Figure 15. Global FcRn Antibodies Market: Chronic Inflammatory Demyelinating Polyneuropathy (2021-2026) & ($ millions)
Figure 16. FcRn Antibodies in Thyroid Eye Disease
Figure 17. Global FcRn Antibodies Market: Thyroid Eye Disease (2021-2026) & ($ millions)
Figure 18. FcRn Antibodies in Graves' Disease
Figure 19. Global FcRn Antibodies Market: Graves' Disease (2021-2026) & ($ millions)
Figure 20. FcRn Antibodies in Sj?gren's Disease
Figure 21. Global FcRn Antibodies Market: Sj?gren's Disease (2021-2026) & ($ millions)
Figure 22. FcRn Antibodies in Systemic Lupus Erythematosus
Figure 23. Global FcRn Antibodies Market: Systemic Lupus Erythematosus (2021-2026) & ($ millions)
Figure 24. FcRn Antibodies in Rheumatoid Arthritis
Figure 25. Global FcRn Antibodies Market: Rheumatoid Arthritis (2021-2026) & ($ millions)
Figure 26. FcRn Antibodies in Other
Figure 27. Global FcRn Antibodies Market: Other (2021-2026) & ($ millions)
Figure 28. Global FcRn Antibodies Market Size Market Share by Application in 2025
Figure 29. Global FcRn Antibodies Revenue Market Share by Player in 2025
Figure 30. Global FcRn Antibodies Market Size Market Share by Region (2021-2026)
Figure 31. Americas FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 32. APAC FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 33. Europe FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 34. Middle East & Africa FcRn Antibodies Market Size 2021-2026 ($ millions)
Figure 35. Americas FcRn Antibodies Value Market Share by Country in 2025
Figure 36. United States FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 37. Canada FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 38. Mexico FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 39. Brazil FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 40. APAC FcRn Antibodies Market Size Market Share by Region in 2025
Figure 41. APAC FcRn Antibodies Market Size Market Share by Type (2021-2026)
Figure 42. APAC FcRn Antibodies Market Size Market Share by Application (2021-2026)
Figure 43. China FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 44. Japan FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 45. South Korea FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 46. Southeast Asia FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 47. India FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 48. Australia FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 49. Europe FcRn Antibodies Market Size Market Share by Country in 2025
Figure 50. Europe FcRn Antibodies Market Size Market Share by Type (2021-2026)
Figure 51. Europe FcRn Antibodies Market Size Market Share by Application (2021-2026)
Figure 52. Germany FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 53. France FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 54. UK FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 55. Italy FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 56. Russia FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 57. Middle East & Africa FcRn Antibodies Market Size Market Share by Region (2021-2026)
Figure 58. Middle East & Africa FcRn Antibodies Market Size Market Share by Type (2021-2026)
Figure 59. Middle East & Africa FcRn Antibodies Market Size Market Share by Application (2021-2026)
Figure 60. Egypt FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 61. South Africa FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 62. Israel FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 63. Turkey FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 64. GCC Countries FcRn Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 65. Americas FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 66. APAC FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 67. Europe FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 68. Middle East & Africa FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 69. United States FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 70. Canada FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 71. Mexico FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 72. Brazil FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 73. China FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 74. Japan FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 75. Korea FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 76. Southeast Asia FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 77. India FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 78. Australia FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 79. Germany FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 80. France FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 81. UK FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 82. Italy FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 83. Russia FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 84. Egypt FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 85. South Africa FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 86. Israel FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 87. Turkey FcRn Antibodies Market Size 2027-2032 ($ millions)
Figure 88. Global FcRn Antibodies Market Size Market Share Forecast by Type (2027-2032)
Figure 89. Global FcRn Antibodies Market Size Market Share Forecast by Application (2027-2032)
Figure 90. GCC Countries FcRn Antibodies Market Size 2027-2032 ($ millions)
